Tumor Biology

, Volume 35, Issue 3, pp 2343–2350 | Cite as

Catechol-O-methyltransferase Val158Met polymorphism and breast cancer risk in Asian population

  • Kai Li
  • Wusheng Li
  • Huawei Zou
Research Article


The association between the polymorphism of catechol-O-methyltransferase (COMT) Val158Met and breast cancer risk is still inconclusive. We performed a meta-analysis to derive a more precise estimation of the relationship. A total of 18 studies including 5,175 cases and 6,463 controls were involved in this meta-analysis. When all studies were pooled into the meta-analysis, no significantly elevated breast cancer risk was associated with all genetic models (for additive model: OR = 1.273, 95 % CI = 0.947–1.711, P heterogeneity = 0.000; P = 0.110; for dominant model: OR = 1.080, 95 % CI = 0.945–1.234, P heterogeneity = 0.001; P = 0.259; for recessive model: OR = 1.242, 95 % CI = 0.941–1.641, P heterogeneity = 0.000; P = 0.126; for allele comparison model: OR = 1.096, 95 % CI = 0.976–1.230, P heterogeneity = 0.000; P = 0.121). In the subgroup analysis by controls source, the same results were found in all genetic models. In summary, this meta-analysis suggests that the COMT Val158Met polymorphism is not a risk factor for breast cancer development. However, large sample and representative population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding.


Catechol-O-methyltransferase COMT Polymorphism Breast cancer Susceptibility 


Conflicts of interest



  1. 1.
    Ahmedin JD, Freddie B, Melissa M. Global cancer statistics 2008. CA Cancer J Clin. 2011Google Scholar
  2. 2.
    McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer epidemiology, risk factors, and genetics. BMJ. 2000;321:624–8.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Sim X, Ali RA, Wedren S, Goh DL, Tan CS, Reilly M. Ethnic differences in the time trend of female breast cancer incidence: Singapore, 1968–2002. BMC Cancer. 2006;6:261.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, Oosterwijk JC. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet. 2002;39:225–42.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999;8:843–54.PubMedGoogle Scholar
  6. 6.
    Lichtenstein P, Holm NV, Verkasalo PK. Environmental and heritable factors in the causation of cancer. N Engl J Med. 2000;343:78–85.PubMedCrossRefGoogle Scholar
  7. 7.
    Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;7:419–24.Google Scholar
  8. 8.
    Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res. 2001;61:6716–22.PubMedGoogle Scholar
  9. 9.
    Goodman JE, Jensen LT, He P, Yager JD. Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics. 2002;12:517–28.PubMedCrossRefGoogle Scholar
  10. 10.
    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRefGoogle Scholar
  11. 11.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  12. 12.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clini Trials. 1986;7:177–88.CrossRefGoogle Scholar
  13. 13.
    Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–7.Google Scholar
  14. 14.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 1999;59:4870–5.PubMedGoogle Scholar
  16. 16.
    Yim DS, Parkb SK, Yoo KY, Yoon KS, Chung HH, Kang HL, et al. Relationship between the Val108/158Met polymorphism of catechol-O-methyl transferase and breast cancer. Pharmacogenetics. 2001;11:279–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Hamajima N, Matsuo K, Tajima K, Mizutani M, Iwata H, Iwase T, et al. Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. Int J Clin Oncol. 2001;6:13–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Wu AH, Tseng CC, Van Den Berg D, Yu MC. Tea intake, COMT genotype, and breast cancer in Asian–American women. Cancer Res. 2003;63:7526–9.PubMedGoogle Scholar
  19. 19.
    Tan W, Qi J, Xing DY, Miao XP, Pan KF, Zhang L, et al. Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women. Zhonghua Zhong Liu Za Zhi. 2003;25:453–6.PubMedGoogle Scholar
  20. 20.
    Lin WY, Chou YC, Wu MH, Jeng YL, Huang HB, You SL, et al. Polymorphic catechol-O-methyl-transferase gene, duration of estrogen exposure, and breast cancer risk: a nested case–control study in Taiwan. Cancer Detect Prev. 2005;29:427–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Lin SC, Chou YC, Wu MH, Wu CC, Lin WY, Yu CP, et al. Genetic variants of myelo-peroxidase and catechol-O-methyltransferase and breast cancer risk. Eur J Cancer Prev. 2005;14:257–61.PubMedCrossRefGoogle Scholar
  22. 22.
    Wen W, Cai Q, Shu XO, Cheng JR, Parl F, Pierce L, et al. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the Shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:329–35.PubMedCrossRefGoogle Scholar
  23. 23.
    Cheng TC, Chen ST, Huang CS, Fu YP, Yu JC, Cheng CW, et al. Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int J Cancer. 2005;113:345–53.PubMedCrossRefGoogle Scholar
  24. 24.
    Chang TW, Wang SM, Guo YL, Tsai PC, Huang CJ, Huang W. Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan. Breast J. 2006;15:754–61.CrossRefGoogle Scholar
  25. 25.
    Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, et al. Prevalence of Val108/158Met polymorphism in COMT gene on non-BRCA1/2 hereditary breast cancer. Zhonghua Wai Ke Za Zhi. 2006;44:1310–3.PubMedGoogle Scholar
  26. 26.
    Hu Z, Song CG, Lu JS, Luo JM, Shen ZZ, Huang W, et al. A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives. J Cancer Res Clin Oncol. 2007;133:969–78.PubMedCrossRefGoogle Scholar
  27. 27.
    Yadav S, Singhal NK, Singh V, Rastogi N, Srivastava PK, Singh MP. Association of single nucleotide polymorphisms in CYP1B1 and COMT genes with breast cancer susceptibility in Indian women. Dis Markers. 2009;27:203–10.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, et al. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer. 2009;125:837–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Syamala VS, Syamala V, Sheeja VR, Kuttan R, Balakrishnan R, Ankathil R. Possible risk modification by polymorphisms of estrogen metabolizing genes in familial breast cancer susceptibility in an Indian population. Cancer Invest. 2010;28:304–11.PubMedCrossRefGoogle Scholar
  30. 30.
    Wang Q, Wang YP, Li JY, Yuan P, Yang F, Li H. Polymorphic catechol-O-methyltransferase gene, soy isoflavone intake and breast cancer in postmenopausal women: a case–control study. Chin J Cancer. 2010;29:683–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Naushad SM, Pavani A, Rupasree Y, Sripurna D, Gottumukkala SR, Digumarti RR, et al. Modulatory effect of plasma folate and polymorphisms in one-carbon metabolism on catecholamine methyltransferase (COMT) H108L associated oxidative DNA damage and breast cancer risk. Indian J Biochem Biophysics. 2011;48(4):283–9.Google Scholar
  32. 32.
    Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:25–243.CrossRefGoogle Scholar
  33. 33.
    Scanlon PD, Raymond FA, Weinshilboum RM. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science. 1979;5:63–5.CrossRefGoogle Scholar
  34. 34.
    Fujisawa T, Ikegami H, Kawaguchi Y, Ogihara T. Meta-analysis of the association of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index. J Clin Endocrinol Metab. 1998;83:2441–4.PubMedGoogle Scholar
  35. 35.
    Liwei L, Chunyu L, Ruifa H. Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis. Urology. 2009;74:884–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of OncologyShengjing Hospital of China Medical UniversityShenyangChina

Personalised recommendations